




3 reasons to consider Dymista® as first-line treatment for seasonal allergic rhinitis¹

Reason 1: Dymista is more effective vs. INS²

Nasal & Ocular symptoms reduction



†p=0.0013 vs. Dymista; ‡p=0.0004 vs. Dymista;

Dymista (n=153); Azelastine hydrochloride (n=152); Fluticasone propionate (n=151)

Reason 2: Dymista provides symptom relief in 5 minutes³



Reason 3: Dymista is recommended for initiation and step-up treatment⁴

Dymista®
(Azelastine Hydrochloride/
Fluticasone Propionate)

[Learn More](#)

Dymista
is now indicated
for patients
6 years and
older¹

Indications and clinical use:

DYMISTA® (azelastine hydrochloride and fluticasone propionate) is indicated for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.

DYMISTA® is not recommended for use in children less than 6 years of age as safety and efficacy have not been established in this age group.

Contraindications:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container
- Patients who have untreated fungal, bacterial, or tuberculosis infections of the respiratory tract

Other relevant warnings and precautions:

- Systemic adverse effects
- Somnolence
- Local nasal adverse effects, inhibitory nasal wound healing, Candida infections, nasal ulceration and nasal septal perforation
- HPA axis adverse effects and effects on growth
- Suppression of immune system; avoid use in infections
- Ophthalmologic adverse effects
- Dysgeusia, epistaxis and headache
- Replacement of a systemic steroid
- Patients with hepatic dysfunction
- Concomitant use with strong CYP3A4 inhibitors and cobicistat-containing products
- Avoid use with alcohol or other central nervous system depressants
- Psychological and behavioural effects
- Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma
- Pregnancy and nursing and risk of hypoadrenalism in newborns

For more information:

Consult the Product Monograph at <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp> for more information about conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions and dosing. The Product Monograph is also available by calling 1-844-596-9526.

INS: intranasal corticosteroids; rT7SS: reflective total of 7 symptom scores

References: 1. Dymista® Product Monograph, May 16, 2022. 2. Meltzer E *et al.* Int Arch Allergy Immunol. 2013;161(4):369-377. 3. Bousquet J *et al.* J Allergy Clin Immunol Pract. 2018;6(5):1726-1732. 4. Bousquet J *et al.* J Allergy Clin Immunol 2020;145:70-80.

DYMISTA® is a registered trademark of Meda AB, licensed use by BGP Pharma ULC, a Viatriis company. VIATRIS and VIATRIS & Design are registered trademarks of Mylan Inc., used under permission by BGP Pharma ULC, a Viatriis company.

©2022 Viatriis Inc. All rights reserved.
DYM-2022-0444E - JL2022

